Charles River Laboratories International Inc. has launched its eXpDNA plasmid platform, established from the company’s contract development and manufacturing (CDMO) and biologics testing experience.
The platform significantly reduces plasmid development and production timelines while streamlining the development journey for cell and gene therapy and vaccine developers with a focus on product quality and consistency.
The platform leverages Charles River’s expertise in developing, manufacturing, and releasing more than 200 High Quality (HQ) and Good Manufacturing Practice- (GMP) compliant plasmid DNA batches. eXpDNA supports a client’s plasmid DNA strategy by offering a proven and standardized plasmid platform approach, suitable for plasmid DNA programs across various applications.
